| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 6.07M | 4.44M | 6.98M | 4.1M | 3.83M | 3.62M | 4.39M | 6.46M | 6.52M | 4.38M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 4.67M | 3.26M | 4.98M | 3.64M | 3.53M | 2.71M | 3.7M | 5.99M | 6.11M | 3.94M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 1.41M | 1.18M | 2M | 460.05K | 301.22K | 916.25K | 690.94K | 468.54K | 407.43K | 438.42K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 10.54K | 0 | 0 | 33.4K | 0 | -249 | -14 | -494 | -8 | 0 |
| Operating Income | -6.07M | -4.44M | -6.98M | -4.1M | -3.83M | -3.62M | -4.39M | -6.46M | -6.52M | -4.38M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 0.56% | 0.27% | -0.57% | 0.41% | 0.07% | 0.05% | -0.21% | -0.47% | -0.01% | 0.33% |
| EBITDA | 0 | 0 | 0 | 0 | 0 | -3.55M | -4.24M | 0 | 0 | 30.66M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 1% | - | - | - | - | - | -0.19% | 1% | - | - |
| D&A (Non-Cash Add-back) | 6.07M | 4.44M | 6.98M | 4.1M | 3.83M | 0 | 0 | 6.46M | 6.52M | 0 |
| EBIT | -6.06M | -4.44M | -6.83M | -4.07M | -3.83M | -3.55M | -4.24M | -6.46M | 333.76K | 30.66M |
| Net Interest Income | -1.19K | -1.54K | 0 | 0 | -452 | -3.04K | 157.14K | 1.94M | 3.4M | 1.42M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 3 | 157.65K | 1.94M | 3.4M | 1.42M |
| Interest Expense | 1.19K | 1.54K | 0 | 0 | 453 | 3.05K | 509 | 0 | 0 | 0 |
| Other Income/Expense | 9.35K | -1.54K | 152.59K | 33.4K | -493 | 71.75K | 152.85K | 2.14M | 6.85M | 35.03M |
| Pretax Income | -6.06M | -4.44M | -6.83M | -4.07M | -3.83M | -3.55M | -4.24M | -4.32M | 333.76K | 30.66M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | -4.88K | -4.44K | 0 | -33.4K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -6.06M | -4.44M | -6.83M | -4.07M | -3.83M | -3.55M | -4.24M | -4.32M | 333.76K | 30.66M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 0.44% | 0.27% | -0.54% | 0.4% | 0.06% | 0.07% | -0.19% | -0.02% | 1.08% | 90.85% |
| Net Income (Continuing) | -6.06M | -4.44M | -6.83M | -4.07M | -3.83M | -3.55M | -4.24M | -4.32M | 333.76K | 30.66M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -12.08 | -7.88 | -10.57 | -5.55 | -4.23 | -2.46 | -0.79 | -0.83 | -1.80 | 3.19 |
| EPS Growth % | 0.48% | 0.35% | -0.34% | 0.47% | 0.24% | 0.42% | 0.68% | -0.05% | -1.17% | 2.77% |
| EPS (Basic) | -12.09 | -7.89 | -10.57 | -5.55 | -4.23 | -2.46 | -0.27 | -0.22 | -1.80 | 3.19 |
| Diluted Shares Outstanding | 501.85K | 563.82K | 646.08K | 733.4K | 903.81K | 1.45M | 5.18M | 5.18M | 9.58M | 7.33M |
| Basic Shares Outstanding | 501.6K | 563.54K | 645.76K | 733.4K | 903.81K | 1.45M | 15.52M | 19.49M | 9.58M | 7.33M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | 0.04% |
| Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.03M | 3.54M | 1.28M | 653.4K | 1.04M | 2.28M | 85.49M | 68.15M | 50.44M | 22.38M |
| Cash & Short-Term Investments | 1.92M | 3.46M | 1.06M | 515.25K | 894.86K | 2.2M | 85.4M | 68.04M | 50.18M | 15.54M |
| Cash Only | 1.92M | 3.46M | 1.06M | 515.25K | 894.86K | 2.2M | 85.4M | 68.04M | 50.18M | 15.17M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 366.32K |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.7M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 74.27K | 224.07K | 138.15K | 0 | 0 | 0 | 0 | 259.8K | 3.14M |
| Total Non-Current Assets | 5.13M | 5.13M | 5.13M | 5.13M | 5.13M | 5.13M | 5.13M | 5.13M | 9.46M | 32.79M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 3.55M | 3.55M | 3.55M | 3.55M | 3.55M | 3.55M | 3.55M | 3.55M | 1.55M | 1.55M |
| Long-Term Investments | 1.57M | 1.57M | 1.57M | 1.57M | 1.57M | 1.57M | 1.57M | 1.57M | 7.91M | 22.47M |
| Other Non-Current Assets | 7.85K | 7.37K | 7.37K | 7.37K | 7.37K | 7.37K | 7.69K | 7.69K | 7.69K | 8.77M |
| Total Assets | 7.16M | 8.67M | 6.41M | 5.78M | 6.17M | 7.4M | 90.62M | 73.28M | 59.9M | 55.17M |
| Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | -0.1% | 0.21% | -0.26% | -0.1% | 0.07% | 0.2% | 11.24% | -0.19% | -0.18% | -0.08% |
| Total Current Liabilities | 637.64K | 580.25K | 644.17K | 742.85K | 1.03M | 724.78K | 704.37K | 586.58K | 7.42M | 2.91M |
| Accounts Payable | 336.01K | 365.6K | 352.62K | 121.89K | 185.84K | 172.26K | 205.36K | 128.28K | 389.37K | 399.2K |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 28.92K | 50.8K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 150.37K | 7.78K | 7.64K | 262.35K | 381.06K | 0 | 380.95K | 345.41K | 6.73M | 0 |
| Current Ratio | 3.18x | 6.10x | 1.99x | 0.88x | 1.01x | 3.14x | 121.38x | 116.18x | 6.80x | 7.68x |
| Quick Ratio | 3.18x | 6.10x | 1.99x | 0.88x | 1.01x | 3.14x | 121.38x | 116.18x | 6.80x | 7.68x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 121.89K | 46.28K | 0 | 0 | 0 | 12.97M | 363K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 46.28K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.97M | 363K |
| Total Liabilities | 637.64K | 580.25K | 644.17K | 742.85K | 1.08M | 724.78K | 704.37K | 586.58K | 20.39M | 3.28M |
| Total Debt | 0 | 0 | 0 | 0 | 75.2K | 50.8K | 0 | 0 | 0 | 0 |
| Net Debt | -1.92M | -3.46M | -1.06M | -515.25K | -819.66K | -2.15M | -85.4M | -68.04M | -50.18M | -15.17M |
| Debt / Equity | - | - | - | - | 0.01x | 0.01x | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.49x |
| Interest Coverage | -5099.08x | -2886.29x | - | - | -8446.79x | -1189.43x | -8628.68x | - | - | - |
| Total Equity | 6.52M | 8.09M | 5.77M | 5.04M | 5.09M | 6.68M | 89.92M | 72.69M | 39.51M | 51.89M |
| Equity Growth % | 0.1% | 0.24% | -0.29% | -0.13% | 0.01% | 0.31% | 12.46% | -0.19% | -0.46% | 0.31% |
| Book Value per Share | 13.00 | 14.34 | 8.93 | 6.87 | 5.63 | 4.61 | 17.37 | 14.04 | 4.12 | 7.08 |
| Total Shareholders' Equity | 6.52M | 8.09M | 5.77M | 5.04M | 5.09M | 6.68M | 89.92M | 72.69M | 39.51M | 51.89M |
| Common Stock | 78.13K | 90.53K | 101.33K | 118.6K | 163.86K | 159 | 2.07K | 2.16K | 2.17K | 2.17K |
| Retained Earnings | -84.69M | -89.14M | -95.96M | -100.03M | -103.86M | -107.41M | -111.65M | -115.96M | -115.63M | -84.97M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -13.56M | -42.04M | -44.61M |
| Accumulated OCI | 806 | 1.74K | -4.71K | -13.84K | -21.71K | -20.38K | -15.76K | -23K | -23.51K | -23.87K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.35M | -3.34M | -5.08M | -2.88M | -2.34M | -3.33M | -4.12M | -3.79M | -2.15M | -2.98M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 0.05% | 0.23% | -0.52% | 0.43% | 0.19% | -0.42% | -0.24% | 0.08% | 0.43% | -0.38% |
| Net Income | -6.06M | -4.44M | -6.83M | -4.07M | -3.83M | -3.55M | -4.24M | -4.32M | 333.76K | 30.66M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.1M | 1.02M | 1.53M | 705.68K | 748.03K | 370.83K | 77.96K | 645.41K | 675 | 478.64K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 491.68K | 107.5K | 309.88K | 316.54K | 473.14K | -4.87K | 34.85K | 174.02K | -2.78M | -35.47M |
| Working Capital Changes | -873.5K | -21.16K | -85.87K | 167.1K | 267.35K | -145.61K | 9.04K | -297.17K | 298.89K | 1.36M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -160.69K | 29.59K | -12.98K | -230.74K | 63.96K | -13.58K | 33.1K | -242.95K | 261.09K | 9.84K |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5M | -7M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 3.57M | 4.88M | 2.68M | 2.34M | 2.73M | 4.64M | 87.31M | -13.56M | -10.71M | -25.03M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.13M |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | 0 | 0 | 0 | -62.38K | -50.75K | 880 | 0 | 1.13M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -4.35M | -3.34M | -5.08M | -2.88M | -2.34M | -3.33M | -4.12M | -3.79M | -2.15M | -2.98M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 0.05% | 0.23% | -0.52% | 0.43% | 0.19% | -0.42% | -0.24% | 0.08% | 0.43% | -0.38% |
| FCF per Share | -8.66 | -5.92 | -7.86 | -3.92 | -2.59 | -2.30 | -0.80 | -0.73 | -0.22 | -0.41 |
| FCF Conversion (FCF/Net Income) | 0.72x | 0.75x | 0.74x | 0.71x | 0.61x | 0.94x | 0.97x | 0.88x | -6.45x | -0.10x |
| Interest Paid | 0 | 1.54K | 0 | 0 | 453 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 800 | 800 | 800 | 800 | 2.27K | 509 | 0 | 1.6K | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -97.35% | -60.84% | -98.57% | -75.26% | -75.58% | -60.4% | -8.78% | -5.31% | 0.59% | 67.08% |
| Return on Invested Capital (ROIC) | -116.22% | -72.23% | -112.21% | -66.62% | -65.27% | -61.77% | -72.82% | -105.59% | - | -25.2% |
| Debt / Equity | - | - | - | - | 0.01x | 0.01x | - | - | - | - |
| Interest Coverage | -5099.08x | -2886.29x | - | - | -8446.79x | -1189.43x | -8628.68x | - | - | - |
| FCF Conversion | 0.72x | 0.75x | 0.74x | 0.71x | 0.61x | 0.94x | 0.97x | 0.88x | -6.45x | -0.10x |
PharmaCyte Biotech, Inc. (PMCB) has a price-to-earnings (P/E) ratio of 0.3x. This may indicate the stock is undervalued or faces growth challenges.
PharmaCyte Biotech, Inc. (PMCB) grew revenue by 0.0% over the past year. Growth has been modest.
PharmaCyte Biotech, Inc. (PMCB) reported a net loss of $8.1M for fiscal year 2025.
Yes, PharmaCyte Biotech, Inc. (PMCB) pays a dividend with a yield of 16.46%. This makes it attractive for income-focused investors.
PharmaCyte Biotech, Inc. (PMCB) has a return on equity (ROE) of 67.1%. This is excellent, indicating efficient use of shareholder capital.
PharmaCyte Biotech, Inc. (PMCB) had negative free cash flow of $4.5M in fiscal year 2025, likely due to heavy capital investments.